Standard BioTools Inc. Company Profile
NASDAQ: LABIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Standard BioTools at a glance
Standard BioTools Inc. (NASDAQ: LAB) is a Biotechnology: Laboratory Analytical Instruments company in the Industrials sector headquartered in Boston, MA. Standard BioTools is led by Dr. Michael Egholm Ph.D. and employs about 385 people. The company's shares have traded publicly since 2011.
At a market capitalization of $249.1 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001162194, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Standard BioTools do?
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Standard BioTools Inc.
- Ticker
- NASDAQ: LAB
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- CEO
- Dr. Michael Egholm Ph.D.
- Employees
- 385
- Headquarters
- 50 Milk Street, Boston, MA, United States
- Phone
- 650 266 6000
- Website
- standardbio.com
- IPO year
- 2011
- Market cap
- $249.11M
- SEC CIK
- 0001162194
- Latest annual report
- 10-K · Mar 16, 2026
Companies similar to Standard BioTools
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NAUTNautilus Biotechnology Inc. | 2.12 | -2.30% | $270.03M | vs LAB |
| QTRXQuanterix Corporation | 1.96 | -3.45% | $93.06M | vs LAB |
| SEERSeer Inc. Class A | 1.36 | -1.81% | $75.91M | vs LAB |
| HBIOHarvard Bioscience Inc. | 8.66 | -0.23% | $39.60M | vs LAB |
| RPIDRapid Micro Biosystems Inc. Class A | 0.735 | -0.04% | $37.37M | vs LAB |
| PRPOPrecipio Inc. | 17.35 | -6.17% | $31.11M | vs LAB |
| EYPTEyePoint Inc. | 0.2342 | -11.36% | $26.65M | vs LAB |
| CIRCCircle8 Group Inc. | 0.1361 | -12.25% | $15.99M | vs LAB |